A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-related adverse events based on the US Food a...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Huqun Li, Chongshu Wang, Aiping Deng, Cuilian Guo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Subjects:	mepolizumab asthma pharmacovigilance disproportionality pediatric long term
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1280490/full